a systematic project. Automatic dehydration machine procedure can obtain better results and greatly improve the efficiency for large slices manipulation of prostate. Background: MDM2 is a mainly negative regulator of p53 tumor suppressor pathway. We aimed to investigate evaluate the association between MDM2 SNP309 polymorphism and bladder cancer risk. Methods: A total of 535 bladder cancer patients and 649 health controls were recruited for our study. MDM2 SNP309 T>G polymorphism was genotyped by PCR-LDR method. Logistic regression was used to analyze the relationship between the genotype and susceptibility of bladder cancer. Kaplan-Meier estimates and log rank
Background:
To investigate the role of miR-186 in the carcinogenesis and metastasis of human urothelial bladder cancer and its potential target protein.
Methods: Quantitative real-time PCR (qRT-PCR) was performed to detect miR-186 expression in human urothelial bladder cancer tissues and cell lines. Then, Bioinformatics analysis, combined with luciferase reporter assay demonstrated the miR-186's target gene and protein.
Finally, the roles of miR-186 in regulation of tumor proliferation and invasion were further investigated by MTT assay and transwell assay. Results: MiR-186 was down-regulated in human urothelial bladder cancer tissues and cell lines. Luciferase reporter assay showed that miR-186 targets HMGN5 3'-untranslated region (UTR) directly and suppresses HMGN5 expression in human urothelial bladder cancer cells. HMGN5 siRNAand miR-186-mediated HMGN5 knock-down experiments revealed that miR-186 suppresses cell proliferation and invasion through suppression of HMGN5 expression.
Expression analysis of a set of epithelial-mesenchymal transition (EMT) markers showed that HMGN5 involves miR-186 suppressed EMT which reducing the expression of mesenchymal markers (vimentin and N-cadherin) and inducing the expression of epithelial marker (E-cadherin). Conclusions: MiR-186 is the upstream regulator of HMGN5. MiR-186-suppressed HMGN5 is a potential novel therapeutic approach for human urothelial bladder cancer. Background: MDM2 is a mainly negative regulator of p53 tumor suppressor pathway. We aimed to investigate evaluate the association between MDM2 SNP309 polymorphism and bladder cancer risk. Methods: A total of 535 bladder cancer patients and 649 health controls were recruited for our study. MDM2 SNP309 T>G polymorphism was genotyped by PCR-LDR method. Logistic regression was used to analyze the relationship between the genotype and susceptibility of bladder cancer. Kaplan-Meier estimates and log rank test were obtained to analyze the association between the genotype and risk of recrudesce in NMIBC patients. A multivariable Cox proportional hazards model was fitted to identify independent prognostic factors. To further investigate the association, we conducted a meta-analysis including six studies. Results: The frequency of the MDM2 SNP309 T>G polymorphism showed no significant difference between cases and controls (all P>0.05). In the stratification analysis, the results showed that G allele carriers were prone to have a significant decrease in risk of low-grade bladder cancer (adjusted OR: 0.613, 95% CI: 0.427-0.881), and G-variant was associated with a significant reduced risk of recurrence in NMIBC patients with or without chemotherapy (P<0.05). The results of mate-analysis showed that G allele and GG genotype of MDM2 SNP309 polymorphism were significant associate with increased risk of bladder cancer in Caucasians (both P<0.05), and no association was observed in total populations and Asians (P<0.05). Conclusions: MDM2 SNP309T>G polymorphism has no influence on bladder cancer risk in Asians, but this SNP may be associated with genetic susceptibility of bladder cancer among Caucasians. Background: Long noncoding RNAs (lncRNAs) have been implicated playing important roles in human urologic cancers. Up to date, quite a few lncRNAs have been implicated as promising biomarkers for tumor early detection and prognosis monitoring. Methods: In the present study, microarray analysis was initially performed to screen the differentially expressed lncRNAs between bladder cancer tissues and paired adjacent non-cancerous tissues (n=3).Subsequent qRT-PCR validation was conducted using tissue samples from 95 patients with bladder cancer. Results: Results showed that the expression level of lncRNA-n336928 (noncode database ID: n336928) was significantly higher in bladder cancer tissues compared to that in adjacent noncancerous tissues (P<0.001). Chisquare test showed that expression of lncRNA-n336928 was positively correlated with bladder tumor stage and histological grade (P<0.001). Kaplan-Meier survival analysis revealed that patients with bladder cancer with high expression of lncRNA-n336928 had shorter overall survival time compared to patients with low expression of lncRNA-n336928. Multivariate analysis indicated that lncRNA-n336928 was an independent prognostic factor for overall survival for bladder cancer patients. Conclusions: our study shows that high expression of lncRNA-n336928 is associated with the progression of bladder cancer, and that lncRNA-n336928 might serve as a biomarker for prognosis of bladder cancer 
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